REGENXBIO appoints Mitchell Chan as CFO; Vittal Vasista steps down after 15 years

REGENXBIO Inc.

Mitchell Chan appointed EVP, CFO effective Sept. 16, 2024; base salary $490K, 40% bonus target, $3M equity grant (75% options, 25% RSUs).
Vittal Vasista resigns after 15+ years; separation allowance $500,018 over 3 installments and up to 75% of 2024 targeted bonus.
Vasista will serve as advisor to CEO through Jan. 3, 2025; unvested equity forfeited after advisory period.
Chan brings 20 years biopharma finance experience; prior CFO of Viela Bio (led $3B Horizon acquisition) and operating partner at Catalio.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Mitchell Chan

Executive Vice President, Chief Financial Officer and Principal Accounting Officer

RGNX · REGENXBIO Inc.

Effective: 2024-09-16
Filed: September 17, 2024, 7:59 PM ET

On September 16, 2024, the board of directors (the “Board” of REGENXBIO Inc. (the “Company”) appointed Mitchell Chan as Executive Vice President, Chief Financial Officer and Principal Accounting Officer, effective immediately.

Departed

Vittal Vasista

Executive Vice President, Chief Financial Officer and Principal Accounting Officer

RGNX · REGENXBIO Inc.

Effective: 2024-09-16
Successor: Mitchell Chan
Filed: September 17, 2024, 7:59 PM ET

the Board accepted the resignation of Vittal Vasista from his position as Executive Vice President, Chief Financial Officer and Principal Accounting Officer, effective as of September 16, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mitchell Chan was appointed as Executive Vice President, Chief Financial Officer and Principal Accounting Officer at REGENXBIO Inc..

Action: appointed
Role: Executive Vice President, Chief Financial Officer and Principal Accounting Officer

Exact text from the filing

On September 16, 2024, the board of directors (the “Board” of REGENXBIO Inc. (the “Company”) appointed Mitchell Chan as Executive Vice President, Chief Financial Officer and Principal Accounting Officer, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Vittal Vasista resigned as Executive Vice President, Chief Financial Officer and Principal Accounting Officer at REGENXBIO Inc..

Action: resigned
Role: Executive Vice President, Chief Financial Officer and Principal Accounting Officer

Exact text from the filing

the Board accepted the resignation of Vittal Vasista from his position as Executive Vice President, Chief Financial Officer and Principal Accounting Officer, effective as of September 16, 2024

View on SEC.gov

REGENXBIO Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-107367

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.